Press Releases

  • Sep. 5, 2012 biOasis’s Herceptin®-BT2111 Stops Human Breast Cancer Tumor Growth in Animals

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that a key animal study in its BT2111 oncology program, showed that BT2111, biOasis’ conjugate of trastuzumab (Herceptin®) designed to treat brain metatastsis of HER2+ breast cancer, arrests the growth tumors in a xenograft model of human breast carcinoma. The human tumor xenograft model is accepted… Read more »

  • Aug. 28, 2012 2012-2013 Board of Directors election, Officers appointment and Option Grant

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX: V BTI) announces its board of directors elected by the shareholders at its Annual General Meeting held today: Robin HutchisonDavid Clark,CADr. Terry PearsonDr. Chris FibigerMichael Hutchison Q.C.Ron EricksonGreg Gubitz The Board also appointed the following officers of the Company: Robin Hutchison, President and CEODavid Clark, Chief Financial Officer… Read more »

  • Jul. 19, 2012 Option Grant – biOasis Technologies Inc.

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX: V BTI) announces that is has granted options to its officers, employees, consultants and members of the board of directors. A total of 1,647,000 options have been granted in accordance with the approved stock option plan, effective at the close of business on July 19, 2012 at a… Read more »

  • Jun. 18, 2012 biOasis Enters Research & Evaluation Agreement with Abbott

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that it has entered into an agreement with Abbott, to evaluate biOasis’s Transcend technology. As consideration for entering into this agreement, undertaking certain activities, and funding a number of experiments, Abbott has been granted certain options to obtain a license to biOasis’ Transcend technology under mutually… Read more »

  • Jun. 11, 2012 biOasis Receives Compelling Data From Texas Tech University On Its Herceptin® BT2111 Program

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that research underway at Texas Tech University Health Sciences Center (TTUHSC) has yielded some compelling data on preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of Transcend and Herceptin®) in animal models of breast cancer metastasis to the brain. The studies were… Read more »

  • May. 31, 2012 biOasis Announces Grant of Stock Options to IR Providers

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V BTI) announces that subject to regulatory approval it will grant additional options in the amount of 50,000 to Brisco Capital Partners Corp. and 50,000 to Graeme Dick pursuant to their IR Consulting Agreement as amended as well as 50,000 to Hamza Thindal Capital Corporation pursuant to their Marketing… Read more »

  • May. 8, 2012 biOasis Transcend Vector Delivers an Anti-Amyloid Beta (A?) Antibody To The Brain – UPDATE – Four (4) Fold Increase In Brain Penetration

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) today announces test results from its Transcend therapeutic development program directed towards the delivery of targeted therapeutic compounds to the brain. The results demonstrate that Transcend can increase considerably the delivery of an anti-amyloid beta antibody (anti-A?) to the brain. Further to the work performed at the National… Read more »

  • Apr. 24, 2012 biOasis Closes Private Placement for $2,484,000 gross proceeds

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) ? is pleased to announce it has closed its non-brokered private placement announced on April 11, 2012. The Company has issued 2,160,000 units, including the maximum over allotment of 360,000 units (20%), at a price of $1.15 per unit, for gross proceeds of $2,484,000. Each… Read more »

  • Apr. 12, 2012 biOasis Announces Non-Brokered Private Placement

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) is pleased to announce a non-brokered private placement of up to 1,800,000 units at a price of $1.15 per unit of gross proceeds of up to $2,070,000 with an overallotment of up to 20%. Each unit will consist of one common share and one full… Read more »

  • Mar. 14, 2012 biOasis’ BT2111-Herceptin? Program Achieves Significant Positive Results From Antibody Dependent Cell-Mediated Cytotoxicity Assay

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) today announces positive test results from its Transcend therapeutic BT2111 development program directed towards the delivery of the therapeutic monoclonal antibody Herceptin? to the brain. An ADCC (antibody dependent cell-mediated cytotoxicity) assay showed that BT2111 conjugates retained Fc receptor binding activity and mediated human immune cell killing of… Read more »